Revolutionizing Brain Health with

AI-Powered EEG Solutions

BrainScope has developed a first-in-class, AI-driven platform that transforms brain electrical activity into a powerful assessment tool. By combining computational neuroscience with a state-of-the-art AI platform, we are unlocking the potential of EEG in ways never before imagined.

CONTACT US

BrainScope's device for head injury assessment was the first device in neurology cleared by the FDA under the AI/Machine Learning-Enabled Medical Device category.
BrainScope has commercialized its first set of FDA-cleared biomarkers for mild brain injury assessment with remarkable outcomes in major U.S. health systems, which include ~50% reduction in unnecessary head CTs and substantial reductions in patient length of stay in emergency departments.

BrainScope's FDA-cleared biomarker for traumatically induced brain bleed assessment could have applicability for assessment of other potentially life-threatening brain issues, such as stroke or ARIA (abnormalities caused by amyloid-reducing Alzheimer's drugs).  

BrainScope’s Large Neural Model Platform goes beyond the limits of traditional EEG and is being used to create new biomarkers
for other CNS indications across the spectrum of brain health and disease.

De-noised & Digitized EEG

Our patent-protected methodologies remove artifacts and improve the quality and interpretability of the EEG signals

Computational Model

Our computational model transforms raw EEG data into actionable insights and can incorporate other clinical datapoints in a multi-modal approach

Novel Biomarkers

Our biomarkers are easy to use, rapid, accessible at the point of care and less expensive than standard diagnostic methods such as neuroimaging.

Validated and Patented

BrainScope has developed an impressive portfolio of 83 issued patents and has commercialized three biomarkers for head injury assessment (10 regulatory clearances).

De-noised and Digitized

Our patent-protected methodologies remove artifacts and improve the quality and interpretability of the EEG signals.

Computational Model

Our computational model transforms raw EEG data into actionable insights and can incorporate other clinical datapoints in a multi-modal approach.

Novel Biomarkers

Our biomarkers are easy to use, rapid, accessible at the point of care and less expensive than standard diagnostic methods such as neuroimaging.

Validated and Patented

BrainScope has developed an impressive portfolio of 83 issued patents and has commercialized three biomarkers for head injury assessment (10 regulatory clearances).

EEG has been used for over a century as a non-invasive, validated technology to provide insights into brain function. However, traditional methods rely on visual inspection, which can often miss the differences between normal and abnormal brain activity.

BrainScope has upended that model by applying machine and deep learning to EEG data, greatly expanding the clinical utility of EEG to aid in assessing and subtyping neurological diseases in ways that have never been done before. We can identify disease-relevant features within EEG starting from the earliest signs of dysfunction, well before structural brain damage occurs.

BrainScope has its own FDA-cleared proprietary device and headset to capture EEG and apply its biomarkers - which is particularly useful in clinical settings where EEG isn’t usually found, like emergency departments. But we don’t need to use our own devices - we can develop and apply novel biomarkers to EEG captured by third-party devices as well.

Background (5)

BrainScope's AI solution tokenizes multi-modal neural data to create bespoke biomarkers to address a range of brain health challenges

LEARN MORE 🡲

headinjury-bg-1

BrainScope's head injury solution is FDA-cleared, clinically validated, and trusted in hospitals and clinics for assessing brain bleeds and concussions.

LEARN MORE 🡲

Early Detection

Identifying brain dysfunction at its earliest stages for more timely intervention.

Tracking Progression

Providing an objective, data-driven approach to evaluate disease progression.

Monitoring Treatment Effects

Helping determine efficacy of therapeutics and identifying potentially dangerous side effects such as ARIA associated with anti-amyloid Alzheimer's drugs.

Digital Neural Twinning and Outcome Prediction

Enabling informed decision-making and patient selection.

Subtyping Disease

Recognizing that there may be more than one form of a disease, and that treatment and treatment response may vary by subtype.